Apotex Gets PTAB To Trim OSI's Cancer Drug Patent
The Patent Trial and Appeal Board on Monday invalidated several claims in an OSI Pharmaceuticals LLC patent that covers its cancer medication Tarceva, as part of an inter partes review requested...To view the full article, register now.
Already a subscriber? Click here to view full article